Institutions / Caxton Corp
Caxton Corp
CIK 1388551 · Institution · as of Mar 31, 2026
Portfolio value
$4.02M
Positions
7
As of
Mar 31, 2026
Portfolio trend
Portfolio value
$4.02M-6.0%Positions
7-36.4%Top holdings
Mar 31, 2026
| Company | Value | % of portfolio |
|---|---|---|
| SPDR Gold Tr | $3.28M | 81.5% |
| Warren E. Buffett | $348.3K | 8.7% |
| Kyverna Therapeutics, Inc.KYTX | $162.0K | 4.0% |
| Lexeo Therapeutics, Inc. | $80.0K | 2.0% |
| X4 Pharmaceuticals, Inc | $64.2K | 1.6% |
| Inhibikase Therapeutics, Inc. | $47.8K | 1.2% |
| ALX Oncology Holdings Inc. | $42.0K | 1.0% |
Activity
Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Exit | Spyre Therapeutics, Inc. Common stock | $-292.2K | -9K -100.00% | 0 | low |
| Q1 2026 as of | Add | 78463V107 Common stock | $283.5K | +659 +9.46% | 7,623 81.50% of portfolio | low |
| Q1 2026 as of | Exit | 60255C885 Common stock | $-210.1K | -16K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Compass Therapeutics, Inc. Common stock | $-158.4K | -29K -100.00% | 0 | low |
| Q1 2026 as of | New | ALX Oncology Holdings Inc. Common stock | $42.0K | +21K | 20,946 1.04% of portfolio | low |
| Q1 2026 as of | Exit | SAB Biotherapeutics, Inc. Common stock | $-39.4K | -11K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Context Therapeutics Inc. Common stock | $-27.1K | -18K -100.00% | 0 | low |
| Q1 2026 as of | Add | Warren E. Buffett Common stock | $8.1K | +17 +2.39% | 727 8.66% of portfolio | low |